Induction with ixazomib-based regimens appear to be insufficient for older patients newly diagnosed multiple myeloma who are ineligible for transplantation, achieving an unsatisfactory progression-free survival (PFS) rate, reports a recent study.
Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.
Despite only being validated for use at diagnosis, risk stratification scores, such as the Mayo-2018 and the International Myeloma Working Group (IMWG)-2020 criteria, appear to be viable for post-diagnosis use in patients with smouldering multiple myeloma (SMM), a recent study has found.
Adding daratumumab to backbone treatments against multiple myeloma (MM) yields high clinical efficacy and has an acceptable toxicity profile, a recent study has found. Such regimens are good treatment options for newly diagnosed (ND) and relapsed/refractory (RR) MM.
Results from the phase III MAIA study showed that the triplet regimen of daratumumab, lenalidomide, and dexamethasone (D-Rd) improved overall survival (OS) compared with lenalidomide plus dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
A treatment combination comprising pomalidomide, bortezomib, and dexamethasone appears to be effective in multiple myeloma patients for whom lenalidomide is no longer an option, including those refractory to lenalidomide, according to the results of the phase III OPTIMISMM trial.
The combination of panobinostat, dexamethasone, and subcutaneous (SC) bortezomib shows promising responses in patients with relapsed or relapsed and refractory multiple myeloma (RRMM), according to the phase II PANORAMA 3* study. Furthermore, SC bortezomib may be preferable to the intravenous (IV) option for reducing toxicity.
Subcutaneous (SC) daratumumab in combination with pomalidomide and dexamethasone (Pd) improves progression-free survival (PFS) and achieves deeper responses vs Pd alone in patients with relapsed/refractory multiple myeloma (R/R MM), results of the phase III APOLLO trial have shown.
Venetoclax in combination with bortezomib and dexamethasone significantly improved progression-free survival (PFS) and response rates in the BELLINI trial in patients with relapsed/refractory (R/R) multiple myeloma (MM), with even greater benefits seen in patients with t(11;14) translocation or high BCL2 gene expression.
Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.